Keymed launches $400m Hong Kong IPO

Jonathan Breen

June 28, 2021 09:30 am

Chinese biotechnology company Keymed Biosciences has hit the market with an up to HK$3.1bn ($400.1m) IPO.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity IPOs Equity China China International Capital Corp Hong Kong SAR Asia Greater China Morgan Stanley Northeast Asia Asia Pacific Emerging Markets

JB

Jonathan Breen

Equities editor GlobalCapital Asia